Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genomic Vision to Extend its Strategic R&D Alliance with Quest Diagnostics

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
Quest Diagnostics will invest in the planned development of a lab-developed test.

Genomic Vision has announced an extension of its strategic alliance agreement with U.S.-based Quest Diagnostics, the world's leading provider of diagnostic information services.

Under the agreement, Quest Diagnostics will invest in the planned development of a lab-developed test for a hereditary genetic disease.

The company will also collaborate with Genomic Vision to automate the testing process and improve turnaround times for tests that employ DNA combing, a technique from Genomic Vision. Additional terms were not disclosed.

"This development is based on the complementary nature of our expertise. The new automated process will help leverage the potential of DNA combing for testing of large populations, which in turn may help improve detection of diseases such as certain cancers and neurological disorders ", stated Aaron Bensimon, CEO of Genomic Vision.

"This development program should make an automated platform available to our customers by the end of 2013, increasing the throughput of our current platform by an order of magnitude", explained Dr. Bensimon.

Genomic Vision and Quest Diagnostics announced a strategic alliance agreement in July 2011 giving Quest exclusive rights in the United States and certain other territories to develop and sell diagnostic tests based on Genomic Vision's molecular combing technology.

Quest Diagnostics (7.4 billion dollars in 2012 revenues with 41,000 employees) has also taken an equity stake in the French biotech company.

Since that time, Quest Diagnostics has adapted the molecular combing technique to a commercial laboratory, streamlined and automated processes and successfully validated an improved molecular combing assay for the genetic disorder facio-scapulo-humeral muscular dystrophy (FSHD). Quest Diagnostics expects to launch the FSHD lab-developed test this summer.

Quest Diagnostics is also exploring market opportunities for a lab-developed test for Lynch Syndrome, which genetically predisposes an individual to colorectal cancer, based on DNA combing.

In 2012, Genomic Vision launched its first test in Europe designed to diagnose facio-scapulo-humeral muscular dystrophy (FSHD), the second most prevalent muscular dystrophy disorder affecting 1 in 10,000 to 1 in 20,000 people.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genomic Vision to extend its strategic R&D alliance with Quest Diagnostic
Under the agreement, Quest Diagnostics will invest in the planned development of a lab-developed test for a hereditary genetic disease.
Tuesday, June 11, 2013
Genomic Vision Receives EUR 473,000 Boost to Technology Development Program
The certification of two of its projects enables the Company to broaden oncology applications and complete technology development.
Tuesday, January 30, 2007
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!